YOLFTbeta
Seres Therapeutics Inc

Seres Therapeutics Inc

MCRB · NASDAQ · Healthcare / Biotechnology

1.40USD-0.01 (-0.71%)

Price History

Full chart

Market Stats

Previous Close1.41
Open1.38
Day Range1.32 – 1.48
52-Week Range3.41 – 29.98
Volume59.95K
Market Cap35.36M
P/E (TTM)0.00
Forward P/E10.26
EPS-2.42
Dividend Yield0.00%
Beta0.21
50-Day Avg4.82
200-Day Avg8.81

About

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Richard N. Kender B.S., M.B.A.
  • Employees66
  • Headquarters101 Cambridgepark Drive, Cambridge, MA, United States, 02140, USA
  • Websitehttps://www.serestherapeutics.com

Leadership

  • Mr. Richard N. Kender B.S., M.B.A.Interim CEO & Executive Chair · b. 1956
  • Dr. Matthew R. Henn Ph.D.President & Chief Scientific Officer · b. 1975
  • Ms. Marella Thorell CPAExecutive VP, CFO & Treasurer · b. 1967
  • Mr. Thomas J. DesRosier Esq., J.D.Executive VP, Chief Legal Officer & Secretary · b. 1955
  • Ms. Kelly Brady M.S.Executive VP & COO · b. 1984
  • Mr. Chris McChalicherExecutive VP & CTO
  • Dr. Dennis M. Walling M.D.Senior VP of Clinical Development & Head of Clinical Research
  • Ms. Ann KurowskiSenior Vice President of Regulatory Affairs

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0021.77M32.10M28.27M34.51M33.22M144.93M7.13M126.33M0789.00K
Growth (%)-----+47.48%-11.94%+22.07%-3.74%+336.33%-95.08%+1672.24%-100.00%-
Cost of Revenue--10.72M728.00K81.99M89.45M95.95M80.14M90.57M141.89M1.00M19.34M3.53M4.13M
Gross Profit---10.72M-728.00K-60.22M-57.35M28.27M34.51M-57.35M144.93M6.12M-19.34M-3.53M-3.34M
Gross Margin-----276.68%-178.68%100.00%100.00%-172.68%100.00%85.91%-15.31%--423.83%
Operating Expense--4.36M54.13M32.62M34.04M128.55M106.38M30.77M209.42M186.04M175.76M117.78M90.63M
Operating Income-3.03M-6.05M-15.08M-54.86M-92.84M-91.39M-100.28M-71.88M-88.13M-64.49M-179.91M-195.10M-121.31M-93.97M
Operating Margin-----426.53%-284.72%-354.77%-208.31%-265.33%-44.50%-2524.05%-154.44%--11910.14%
EBITDA-3.01M-5.96M-14.89M-54.13M-88.63M-82.12M-92.42M-62.17M-77.31M-56.72M-170.93M-181.42M-120.30M9.83M
EBITDA Margin-----407.21%-255.83%-326.96%-180.19%-232.76%-39.14%-2398.04%-143.61%-1245.75%
Net Income-3.13M-6.10M-16.71M-54.78M-91.58M-89.38M-98.94M-70.28M-89.13M-65.58M-250.16M-113.72M-146.57M5.70M
Net Income Margin-----420.74%-278.44%-350.03%-203.68%-268.33%-45.25%-3509.50%-90.02%-721.93%
R&D2.08M4.80M10.72M38.09M81.99M89.45M95.95M80.14M90.57M141.89M109.65M117.60M64.60M49.06M
R&D as % of Total Revenue----376.68%278.68%339.46%232.26%272.68%97.91%1538.31%93.09%-6218.00%
Interest Expense042.00K0555.00K969.00K1.59M1.17M502.00K2.92M2.91M6.02M13.18M00
Interest Expense % of Total Revenue----4.45%4.95%4.15%1.45%8.80%2.01%84.46%10.43%-0.00%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.54M2.13M117.34M216.90M272.65M189.52M120.47M132.44M342.94M354.86M348.78M358.60M139.81M138.19M
Total Liabilities178.00K1.49M144.07M11.51M140.01M128.82M168.52M180.76M168.19M223.35M338.00M403.46M126.03M93.97M
Total Equity6.36M631.00K-26.72M205.39M132.63M60.70M-48.05M-48.32M174.75M131.51M10.78M-44.86M13.78M44.22M
Cash6.21M1.65M114.19M73.93M54.54M36.09M85.82M65.13M116.05M180.00M163.03M127.97M30.79M45.77M
Total Debt-838.00K2.50M-10.73M8.99M7.25M44.78M40.77M49.21M162.59M198.78M91.64M82.97M
Net Debt-6.21M-816.00K-111.68M-73.93M-43.81M-27.10M-78.57M-20.35M-75.28M-130.79M-440.00K70.82M60.85M37.20M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.92M-5.32M-10.36M-40.84M43.92M-75.52M-62.85M-76.52M-93.61M6.69M-228.82M-117.35M-148.61M1.12M
Investing Cash Flow-319.00K-184.00K-1.10M-137.13M-65.45M56.99M112.32M-30.52M-158.89M64.09M82.43M10.58M142.29M-42.00K
Financing Cash Flow9.44M944.00K123.99M137.72M2.14M83.00K268.00K86.23M303.42M1.18M129.60M71.70M-90.37M13.90M
Capital Expenditure292.00K174.00K1.00M4.36M21.49M4.68M1.94M1.00M591.00K9.57M9.82M7.97M380.00K252.00K
Free Cash Flow-3.22M-5.50M-11.36M-45.21M22.43M-80.20M-64.79M-77.52M-94.20M-2.88M-238.64M-125.33M-148.99M865.00K
Dividends Paid---262.00K00--------
FCF to OCF109.98%103.27%109.66%110.68%51.07%106.19%103.08%101.31%100.63%-43.03%104.29%106.80%100.26%77.44%
Dividend Paid to FCF----0.58%0.00%0.00%--------

Earnings

Report DateAug 6, 2015Nov 10, 2015Feb 25, 2016May 16, 2016Aug 11, 2016Nov 10, 2016Mar 16, 2017May 4, 2017Aug 3, 2017Nov 8, 2017Mar 8, 2018May 9, 2018Aug 2, 2018Nov 8, 2018Mar 6, 2019May 2, 2019Aug 6, 2019Nov 5, 2019Mar 2, 2020May 7, 2020Jul 28, 2020Nov 9, 2020Mar 2, 2021May 4, 2021Aug 3, 2021Nov 10, 2021Mar 1, 2022May 4, 2022Aug 3, 2022Nov 2, 2022Mar 7, 2023May 9, 2023Aug 8, 2023Nov 2, 2023Mar 5, 2024May 8, 2024Aug 13, 2024Nov 13, 2024Mar 3, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Mar 12, 2026May 5, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate-4.90-6.35-8.24-9.27-8.93-10.46-0.72-13.13-12.76-9.90-0.75-15.25-14.00-10.92-0.50-9.20-10.35-5.27-5.27-0.28-5.16-5.00-0.28-6.30-7.63-3.46-0.44-10.04-12.30-9.44-0.46-10.8510.97-10.65-0.50-7.25-5.91-0.04-0.201.97-2.270.05-1.60-1.88-2.07-1.34
EPS Actual-6.60-7.60-8.20-10.00-14.00-9.20-0.63-12.60-13.80-3.40-0.72-13.80-13.60-10.80-0.52-11.13-4.80-4.60-5.00-0.28-5.60-7.20-0.23-7.80-10.6014.40-0.52-12.20-14.00-9.80-0.54-11.407.20-7.40-0.32-5.40-4.40-6.60-0.11-2.24-2.270.94-1.76-2.08-1.50-
Surprise-34.69%-19.68%0.49%-7.87%-56.77%12.05%12.50%4.04%-8.15%65.66%4.00%9.51%2.86%1.10%-4.00%-20.98%53.62%12.71%5.12%0.00%-8.53%-44.00%17.86%-23.81%-38.93%516.18%-18.18%-21.51%-13.82%-3.81%-17.39%-5.07%-34.37%30.52%36.00%25.52%25.55%-16400.00%44.81%-213.71%0.00%1780.00%-10.00%-10.64%27.54%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap35.36M
Enterprise Value81.43M
Trailing P/E0.00
Forward P/E10.26
PEG Ratio-0.11
Price / Sales18.78
Price / Book1.17
EPS-2.42
Book Value3.51
Revenue (TTM)1.88M
Gross Profit (TTM)-46.08M
EBITDA-74.78M
Profit Margin0.00%
Operating Margin-2101.36%
Return on Equity-66.57%
Return on Assets-39.85%
Shares Outstanding10.04M
Shares Float8.73M
Beta0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 17.00
  • Strong Buy
    2
  • Hold
    2
  • Sell
    1

Ownership Breakdown

Institutions
22.99%
Insiders
11.49%
Retail / Other
65.52%

Top Institutional Holders

  • Flagship Ventures Management, Inc.
    1.16M11.51%
  • Vanguard Capital Management, LLC
    294.14K2.93%
  • Marshall Wace Asset Management Ltd
    139.54K1.39%
  • Vontobel Holding Ltd.
    122.97K1.22%
  • Susquehanna International Group, LLP
    105.34K1.05%
  • BlackRock Inc
    102.03K1.02%
  • Geode Capital Management, LLC
    74.83K0.74%
  • Vanguard Fiduciary Trust Co
    39.64K0.39%
  • State Street Corp
    33.90K0.34%
  • Charles Schwab Investment Management Inc
    31.63K0.31%
  • Lion Point Capital, LP
    31.57K0.31%
  • American Century Companies Inc
    28.31K0.28%
  • Morgan Stanley - Brokerage Accounts
    21.70K0.22%
  • Northern Trust Corp
    14.77K0.15%
  • Amvescap Plc.
    14.55K0.14%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    206.17K2.05%
  • Fidelity Extended Market Index
    36.63K0.36%
  • Schwab US Small-Cap ETF™
    30.83K0.31%
  • iShares Micro-Cap ETF
    25.22K0.25%
  • Fidelity Total Market Index
    13.87K0.14%

Stock Splits

  • Apr 22, 20251:20